Medifast Inc: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 7, 2023 and accepted by EDGAR at Aug 7, 2023, 16:50 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $296.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $645.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $85.5m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $188.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2023-04-01 to 2023-06-30 | $210.7m | us-gaap:GrossProfit |
| Gross profit | 6 months2023-01-01 to 2023-06-30 | $457.1m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2023-04-01 to 2023-06-30 | $172.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-01-01 to 2023-06-30 | $364.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | $38.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | $92.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-04-01 to 2023-06-30 | $8.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-01-01 to 2023-06-30 | $22.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | $30.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | $70.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | $2.77 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-06-30 | $6.43 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | $2.78 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | $6.46 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 10,917,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 10,923,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | $107.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $3.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2023-01-01 to 2023-06-30 | $37.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 6 months2023-01-01 to 2023-06-30 | $3.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-06-30 | $147.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $228.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $318.7m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $114.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $133.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-06-30 | $185.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-027815. Last ingested by Listed: Oct 31, 2026, 14:35 ET. Listed shows no prices and gives no investment advice.